The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
Open accessAbstract
The promising drug candidate indazolium trans‐[tetrachlorobis(1 H‐indazole)ruthenate(III)] (KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review, which is an update of a paper from 2006 (Hartinger et al., J. Inorg. Biochem. 2006, 100, 891–904), the experimental evidence for the proposed mode of action of this coordination compound is discussed, including transport into the cell via the transferrin cycle and activation by reduction. The results of the early clinical development of KP1019 are summarized in which five out of six evaluated patients experienced disease stabilization with no severe side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Cited by
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Metal-NHC complexes: a survey of anti-cancer properties
Teyssot, M.-L., Jarrousse, A.-S., Manin, M., Chevry, A., Roche, S., Norre, F., Beaudoin, C., Morel, L., Boyer, D., Mahiou, R., et al. (2009) · Dalton Transactions · doi:10.1039/b906308k · Cited by 384
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Self-citationAnticancer cyclometalated complexes of platinum group metals and gold
Cutillas, N., Yellol, G. S., de Haro, C., Vicente, C., Rodríguez, V., & Ruiz, J. (2013) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2013.03.024 · Cited by 332
Metal-based drugs that break the rules
Allardyce, C. S., & Dyson, P. J. (2016) · Dalton Transactions · doi:10.1039/c5dt03919c · Cited by 308
Self-citation
Metadata
- Authors
- Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K.
- Venue
- Chemistry & Biodiversity
- Publisher
- Wiley
- Published
- 2008-10
- Volume
- 5
- Issue
- 10
- Pages
- 2140-2155
- ISSN
- 1612-1872 (ISSN-L)
- 1612-1880
- OpenAlex
- W2005723165
- Cited by
- 830
- References
- 1
- FWCI
- 15.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients. https://app.cochat.ai/papers/10.1002/cbdv.200890195
- The paper
- Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008). KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.200890195
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
